Compare LTH & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTH | KRYS |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.3B |
| IPO Year | 2021 | 2017 |
| Metric | LTH | KRYS |
|---|---|---|
| Price | $25.56 | $233.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 9 |
| Target Price | $37.50 | ★ $214.22 |
| AVG Volume (30 Days) | ★ 2.0M | 274.5K |
| Earning Date | 11-04-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 88.46 | ★ 275.72 |
| EPS | 1.28 | ★ 6.66 |
| Revenue | ★ $2,913,442,000.00 | $373,164,000.00 |
| Revenue This Year | $15.07 | $36.14 |
| Revenue Next Year | $10.88 | $41.80 |
| P/E Ratio | ★ $19.93 | $35.13 |
| Revenue Growth | 15.77 | ★ 54.51 |
| 52 Week Low | $21.49 | $122.80 |
| 52 Week High | $34.99 | $241.20 |
| Indicator | LTH | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 80.39 |
| Support Level | $24.46 | $213.83 |
| Resistance Level | $27.11 | $221.84 |
| Average True Range (ATR) | 0.68 | 7.76 |
| MACD | 0.01 | 1.37 |
| Stochastic Oscillator | 32.48 | 79.71 |
Life Time Group Holdings Inc is a lifestyle and leisure brand offering health, fitness, and wellness experiences to a community. It is engaged in designing, building, and operating distinctive and large, multi-use sports and athletic, professional fitness, family recreation, and spa centers in a resort-like environment, principally in residential locations of metropolitan areas in the United States and Canada.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.